MPO and lupus nephritis: It does have a good efficacy to reduce NETs in COVID-triggered acute respiratory distress syndrome via inhaled route or when administered intravenously in lupus nephritis patients and anti-MPO ANCA mouse model, however, intravenous or subcutaneous administration failed to achieve sufficient bioactive serum concentration in humans (94, 110, 111).